Welcome to the Autumn edition of BioBrief, our quarterly newsletter providing essential updates and analysis for those working in the life sciences sector.

In this edition you will find:

> A videocast on the recent decision of the Patents Court to uphold the validity of an important Astellas patent protecting their blockbuster product Mirabegron
> An article on how the UK is moving into the fast lane for biosimilar regulatory approvals
> An article outlining the new UK immigration routes in 2022
> Our newly developed SCC toolkit which will help you understand whether your organisation will be impacted by the old EU Standard Contractual Clauses needing to be replaced by the 27 December
> A video summary of the controversial aspects of the debate currently taking place at the WTO level concerning patent waivers on diagnostics, vaccines and therapies for COVID-19 infection
> A closer look at what you need to know about the new In Vitro Diagnostic Medical Devices Regulation
> The proposed UK Framework for Medical Device Regulations

Please see the full newsletter here: https://publication.penningtonslaw.com/cv/ebc27cf3cd55545a4bbf15c88d0fc…